Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

ABSTRACT: exosomes isolated from: HT29+control shRNA; HT29+p53 shRNA; HCT116 WT p53; HCT116 mutant p53; HCT116 null p53; media used as negative control

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Lisa Jenkins

PROVIDER: MSV000082047 | MassIVE | Fri Feb 09 05:43:00 GMT 2018

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Similar Datasets

Identification of p53-regulated genes in wild-type p53 or p53-null HCT116 cells

Project description:Identification of p53-regulated genes in wild-type p53 or p53-null HCT116 cells

| PRJNA517505 | ENA

The DNA binding selectivity by wild-type p53 and PANDAs

Project description:We performed ChIP-seq analysis of p53-null HCT116 cells stably expressed wild-type p53 or mutant p53 followed by ATO treatment (PANDAs) to identify p53 binding characteristics by wild-type p53 and PANDAs.

2024-01-31 | GSE195622 | GEO

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246.

Project description: Not available

| S-EPMC5823939 | biostudies-literature

Gene expression profiling of CYC116 and ZM447439 resistant HCT116 wild type and HCT116 p53 null clones in comparison to parent cell lines

Project description:HCT116 and HCT116 p53 null were exposed to two Aurora kinase inhibitors (CYC116 and ZM447439) at cytotoxic concentrations. Within 4-5 weeks we were able to select and isolate 10 drug resistant clones from each group. 3 clones were selected for gene expression profiling using Affymetrix microarrays (Human Gene 1.0 ST Array). The samples in each group were initially given the code names as follows. Group 1. [R1.3, R4.2, R6.3: CYC116 p53 wild type], Group 2. [R8.7, R9.7, R10.7:CYC116 p53 null], Group 3. [R7.1, R15.1, R16.1:ZM447439 p53 wild type], and Group 4. [R1.5, R3.5, R4.5:ZM447439 p53 null). For publication purpose the names were later changed to, Group 1. [R1.1, R1.2, R1.3: CYC116 p53 wild type], Group 2. [R2.1, R2.2, R2.3:CYC116 p53 null], Group 3. [R3.1, R3.2, R3.3:ZM447439 p53 wild type], and Group 4. [R4.1, R4.2, R4.3:ZM447439 p53 null].

2012-04-01 | E-MEXP-3526 | biostudies-arrayexpress

Selective and direct p53 inhibition by iASPP

Project description:We performed p53 ChIP-seq analysis of Nutlin-treated HCT116 cells to identify high-confident p53 regulated targets. And we performed ChIP-seq using an anti-p53 antibody in HCT116 cells treated with control or iASPP RNAi to identify iASPP regulated p53 targets.

2019-09-23 | GSE113338 | GEO

Identification of p53-regulated genes in wild-type p53 or p53-null HCT116 cells

Project description:Microarray-based gene expression analysis of HCT116 p53+/+ and HCT116 p53−/− treated with doxorubicin to activate p53 in time-dependent manner.

2019-01-29 | GSE125787 | GEO

Identification of Genes Preferentially Required for Growth of p53-Deficient Human Cancer Cells

Project description:We describe a synthetic interaction screen to identify genes preferentially required for proliferation of p53-deficient human cancer cells. An isogenic pair of p53+/+ and p53-/- human colorectal HCT116 cell lines was stably transduced with a short hairpin RNA (shRNA) library encoded by lentiviruses that integrate in the genomic DNA of the host. Comparison of the frequency of each type of integrated lentivirus in the 2 cell types at an early time point (40hrs) and after about 12 mitotic cycles (10days), reveals genes whose knockdown preferentially impaired growth of p53-/- or p53+/+ HCT116 cells. Keywords: Functional Genomics

2010-05-01 | GSE15967 | GEO

Identification of Genes Preferentially Required for Growth of p53-Deficient Human Cancer Cells

2010-05-01 | E-GEOD-15967 | biostudies-arrayexpress

Role of SMAR1 in global gene regulation through interaction with tumor suppressor p53

Project description:Scaffold Matrix Attachment Region binding protein 1, SMAR1 has vital role to play as a general repressor of transcription. SMAR1 is known to retard cell cycle progression and delay tumor growth in mice. Further, it forms a ternary complex with p53-Mdm2 and inhibit p53-mediated transcription. Thus, SMAR1 can potentially alter p53 function and orchestrate different set of genes in p53-dependent and p53-independent manner. The present study aims to decipher the potential role of SMAR1 in global transcription regulation and to study role of p53 in the process. Towards this objective, chromatin immunoprecipitation combined Next-generation sequencing (ChIP-Seq) was performed using HCT116 and HCT116 p53-/- cell samples. The α-SMAR1 antibody was used for such ChIP experiments which was already tested by Wastern blot assays and found to be SMAR1 specific. The sequence data generated was then analyzed and the results obtained are (1) Higher genomic occupancy of SMAR1 in HCT116 (wild type) than HCT116 p53-/- (P53 null) data set (2) For peaks within ±5kb of TSS, SMAR1 had the highest predisposition to bind upstream of the TSS in close proximity, i.e., -1 to 0 kb that represents the promoter region of the gene (3) SMAR1 was found to target 5617 genes (unique in Wild type) , 8198 genes (unique in Null) and 1876 genes that were common in both the samples (4) In silico motif search indicated that SMAR1 binds to a dinucleotide T(C/G) repeat sequence (5) Functional Annotation of targets revealed that the predicted target genes are involved in apoptosis, epigenetics, cell cycle, cell signalling, neuronal genes, transcription, metabolism etc. The target also include noncoding RNAs genes such as microRNAs /lincRNAs.

2016-10-13 | GSE70058 | GEO

RNAseq expression of p53-null and p53-null/PLK2-null mammary tumors

Project description:RNAseq expression of p53-null and p53-null/PLK2-null mammary tumors

| PRJNA731110 | ENA